Gene · 8912
Papers1,764
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 1,764
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Sulfide and polysulfide as pronociceptive mediators: Focus on Cav3.2 function enhancement and TRPA1 activation. | J Pharmacol Sci | 2024 | 38797535 | PubTator, text mining | PubMed |
| A Review of the CACNA Gene Family: Its Role in Neurological Disorders. | Diseases | 2024 | 38785745 | PubTator, text mining | PubMed |
| Genome-wide DNA Methylome and Transcriptome Profiling Reveals Key Genes Involved in the Dysregulation of Adipose Stem Cells in Crohn's Disease. | J Crohns Colitis | 2024 | 38747506 | PubTator, text mining | PubMed |
| A novel model combining genes associated with disulfidptosis and glycolysis to predict breast cancer prognosis, molecular subtypes, and treatment response. | Environ Toxicol | 2024 | 38747344 | PubTator, text mining | PubMed |
| A tale of two calcium channels: structural pharmacology of Cav2.1 and Cav3.2. | Cell Res | 2024 | 38702487 | PubTator, text mining | PubMed |
Endoplasmic reticulum stress produced by Thapsigargin affects the occurrence of spike-wave discharge by modulating unfolded protein response pathways and activating immune responses in a dose-dependent manner. | Eur J Pharmacol | 2024 | 38670446 | PubTator, text mining | PubMed |
| Elevated microRNA-214-3p level ameliorates neuroinflammation after spinal cord ischemia-reperfusion injury by inhibiting Nmb/Cav3.2 pathway. | Int Immunopharmacol | 2024 | 38631219 | PubTator, text mining | PubMed |
| Structural basis for human Cav3.2 inhibition by selective antagonists. | Cell Res | 2024 | 38605177 | PubTator, text mining | PubMed |
| The mmu_circ_003062, hsa_circ_0075663/miR-490-3p/CACNA1H axis mediates apoptosis in renal tubular cells in association with endoplasmic reticulum stress following ischemic acute kidney injury. | Int Immunopharmacol | 2024 | 38554447 | PubTator, text mining | PubMed |
| Multi-omics approaches for drug-response characterization in primary biliary cholangitis and autoimmune hepatitis variant syndrome. | J Transl Med | 2024 | 38424613 | PubTator, text mining | PubMed |
| Genomic evidence for the suitability of Göttingen Minipigs with a rare seizure phenotype as a model for human epilepsy. | Neurogenetics | 2024 | 38383918 | PubTator, text mining | PubMed |
| α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes. | Transl Neurodegener | 2024 | 38378800 | PubTator, text mining | PubMed |
| Effect of ABT-639 on Cav3.2 channel activity and its analgesic actions in mouse models of inflammatory and neuropathic pain. | Eur J Pharmacol | 2024 | 38342359 | PubTator, text mining | PubMed |
| A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients. | Int Immunopharmacol | 2024 | 38325047 | PubTator, text mining | PubMed |
| What We Know about and What Is New in Primary Aldosteronism. | Int J Mol Sci | 2024 | 38255973 | PubTator, text mining | PubMed |
| An orally available Cav2.2 calcium channel inhibitor for the treatment of neuropathic pain. | Br J Pharmacol | 2024 | 38157867 | PubTator, text mining | PubMed |
| Time-of-day-dependent variation of the human liver transcriptome and metabolome is disrupted in MASLD. | JHEP Rep | 2024 | 38125300 | PubTator, text mining | PubMed |
| Cav3.2 T-Type Calcium Channel Mediates Acute Itch and Contributes to Chronic Itch and Inflammation in Experimental Atopic Dermatitis. | J Invest Dermatol | 2024 | 37863387 | PubTator, text mining | PubMed |
| MiRNA-26a-5p inhibits preterm labor initiation by targeting and regulating TRPC3 ion channel protein expression. | Environ Toxicol | 2024 | 37755144 | PubTator, text mining | PubMed |
| Role of Cav2.3 (R-type) Calcium Channel in Pain and Analgesia: A Scoping Review. | Curr Neuropharmacol | 2024 | 37581322 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8912/papers?page=6